Cargando…
Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model
PURPOSE: Success in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internist...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495448/ https://www.ncbi.nlm.nih.gov/pubmed/28717689 http://dx.doi.org/10.1200/JGO.2015.000067 |
_version_ | 1783247808692748288 |
---|---|
author | Shyirambere, Cyprien Xu, Mary Jue Elmore, Shekinah Nefreteri Fadelu, Temidayo May, Leana Tapela, Neo Umuhizi, Denis Gilbert Uwizeye, Frank Regis Driscoll, Caitlin Muhayimana, Clemence Hategekimana, Vedaste Rubagumya, Fidel Nzayisenga, Ignace Shulman, Lawrence N. Mpunga, Tharcisse Lehmann, Leslie E. |
author_facet | Shyirambere, Cyprien Xu, Mary Jue Elmore, Shekinah Nefreteri Fadelu, Temidayo May, Leana Tapela, Neo Umuhizi, Denis Gilbert Uwizeye, Frank Regis Driscoll, Caitlin Muhayimana, Clemence Hategekimana, Vedaste Rubagumya, Fidel Nzayisenga, Ignace Shulman, Lawrence N. Mpunga, Tharcisse Lehmann, Leslie E. |
author_sort | Shyirambere, Cyprien |
collection | PubMed |
description | PURPOSE: Success in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internists and pediatricians, and data collection structured for monitoring and evaluation. Here, we report clinical outcomes and protocol compliance for patients with nephroblastoma evaluated at Butaro Cancer Center of Excellence in Rwanda. PATIENTS AND METHODS: This retrospective study reports the care of 53 patients evaluated between July 1, 2012, and June 30, 2014. Patients receiving less than half of their chemotherapy at Butaro Cancer Center of Excellence were excluded. RESULTS: Of the 53 patients included, 9.4% had stage I, 13.2% had stage II, 24.5% had stage III, 26.4% had stage IV, and 5.7% had stage V disease; the remaining 20.8% had unknown stage disease from inadequate work-up or unavailable surgical report. The incidence of neutropenia increased with treatment progression, and the greatest proportion of delays occurred during the surgical referral phase. At the end of the study period, 32.1% of patients (n = 17) remained alive after treatment; 24.5% (n = 13) remained alive while continuing treatment, including one patient with recurrent disease; 30.2% (n = 16) died; and 13.2% (n = 7) were lost to follow-up. CONCLUSION: Our findings confirm that nephroblastoma can be effectively treated in resource-constrained settings. Using an approach in which chemotherapy is delivered at a rural-based center by nononcologists and data are used for routine evaluation, care can be delivered in safe, novel ways. Protocol modifications to mitigate chemotherapy toxicities and strong communication between the multidisciplinary team members will likely minimize delays and further improve outcomes in similar settings. |
format | Online Article Text |
id | pubmed-5495448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-54954482017-07-17 Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model Shyirambere, Cyprien Xu, Mary Jue Elmore, Shekinah Nefreteri Fadelu, Temidayo May, Leana Tapela, Neo Umuhizi, Denis Gilbert Uwizeye, Frank Regis Driscoll, Caitlin Muhayimana, Clemence Hategekimana, Vedaste Rubagumya, Fidel Nzayisenga, Ignace Shulman, Lawrence N. Mpunga, Tharcisse Lehmann, Leslie E. J Glob Oncol Original Reports PURPOSE: Success in treating nephroblastoma in high-income countries has been transferred to some resource-constrained settings; multicenter studies report disease-free survival of greater than 70%. However, few reports present care models with rural-based components, care tasks shifted to internists and pediatricians, and data collection structured for monitoring and evaluation. Here, we report clinical outcomes and protocol compliance for patients with nephroblastoma evaluated at Butaro Cancer Center of Excellence in Rwanda. PATIENTS AND METHODS: This retrospective study reports the care of 53 patients evaluated between July 1, 2012, and June 30, 2014. Patients receiving less than half of their chemotherapy at Butaro Cancer Center of Excellence were excluded. RESULTS: Of the 53 patients included, 9.4% had stage I, 13.2% had stage II, 24.5% had stage III, 26.4% had stage IV, and 5.7% had stage V disease; the remaining 20.8% had unknown stage disease from inadequate work-up or unavailable surgical report. The incidence of neutropenia increased with treatment progression, and the greatest proportion of delays occurred during the surgical referral phase. At the end of the study period, 32.1% of patients (n = 17) remained alive after treatment; 24.5% (n = 13) remained alive while continuing treatment, including one patient with recurrent disease; 30.2% (n = 16) died; and 13.2% (n = 7) were lost to follow-up. CONCLUSION: Our findings confirm that nephroblastoma can be effectively treated in resource-constrained settings. Using an approach in which chemotherapy is delivered at a rural-based center by nononcologists and data are used for routine evaluation, care can be delivered in safe, novel ways. Protocol modifications to mitigate chemotherapy toxicities and strong communication between the multidisciplinary team members will likely minimize delays and further improve outcomes in similar settings. American Society of Clinical Oncology 2016-01-27 /pmc/articles/PMC5495448/ /pubmed/28717689 http://dx.doi.org/10.1200/JGO.2015.000067 Text en © 2016 by American Society of Clinical Oncology http://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Reports Shyirambere, Cyprien Xu, Mary Jue Elmore, Shekinah Nefreteri Fadelu, Temidayo May, Leana Tapela, Neo Umuhizi, Denis Gilbert Uwizeye, Frank Regis Driscoll, Caitlin Muhayimana, Clemence Hategekimana, Vedaste Rubagumya, Fidel Nzayisenga, Ignace Shulman, Lawrence N. Mpunga, Tharcisse Lehmann, Leslie E. Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model |
title | Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model |
title_full | Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model |
title_fullStr | Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model |
title_full_unstemmed | Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model |
title_short | Treating Nephroblastoma in Rwanda: Using International Society of Pediatric Oncology Guidelines in a Novel Oncologic Care Model |
title_sort | treating nephroblastoma in rwanda: using international society of pediatric oncology guidelines in a novel oncologic care model |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495448/ https://www.ncbi.nlm.nih.gov/pubmed/28717689 http://dx.doi.org/10.1200/JGO.2015.000067 |
work_keys_str_mv | AT shyiramberecyprien treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT xumaryjue treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT elmoreshekinahnefreteri treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT fadelutemidayo treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT mayleana treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT tapelaneo treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT umuhizidenisgilbert treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT uwizeyefrankregis treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT driscollcaitlin treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT muhayimanaclemence treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT hategekimanavedaste treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT rubagumyafidel treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT nzayisengaignace treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT shulmanlawrencen treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT mpungatharcisse treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel AT lehmannlesliee treatingnephroblastomainrwandausinginternationalsocietyofpediatriconcologyguidelinesinanoveloncologiccaremodel |